Navamedic ASA (Lysaker, Norway, 12 June 2008) Navamedic has been informed that the reimbursement process in France is delayed. As a consequence, it is uncertain whether Glucomed will be launched in France during 2008.

Navamedic still believes that the French market is interesting.

For further information, please contact:

Øyvind W. Brekke, CEO Navamedic ASA E-mail: oyvind.brekke@navamedic.com Office: +47 67 11 25 40 Mobile: +47 91 19 81 64

Bernt-Olav Røttingsnes, CFO/IRO Navamedic ASA E-mail: bor@navamedic.com Office: +47 67 11 25 44 Mobile: +47 91 34 70 21

Navamedic ASA

http://www.navamedic.com

ISIN: NO0010205966

Stock Identifier: XOSL.NAVA

ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 3) (Last 30 Days: 7) (Since Published: 726)